Health Canada has provided authorization to market Jubbonti® (denosumab subcutaneous injection, reference medicine: Prolia).
Jubbonti® is the first and only Health Canada-approved denosumab biosimilar for osteoporosis and increasing bone mass. This human monoclonal antibody and RANK ligand inhibitor (bone metabolism regulator) is approved to treat all five indications covered by the reference medicine and is available as a 60 mg/mL solution in single-use prefilled syringe. Jubbonti® should be available on the Canadian market in the coming months.
“This announcement means that Canadians will have greater access to an important biologic therapy in the treatment of osteoporosis,” says Dr. Famida Jiwa, President and CEO, Osteoporosis Canada. “Health Canada’s approval of the denosumab biosimilar Jubbonti®will expand and increase access to patients who are living with osteoporosis.”
Click here to visit Sandoz and read the full release.
